Objective: To assess the efficacy of a chlorhexidine-impregnated dressing for prevention of central venous catheter-related colonization and catheter-related bloodstream infection using meta-analysis. Data Sources: Multiple computerized database searches supplemented by manual searches including relevant conference proceedings. Study Selection: Randomized controlled trials evaluating the efficacy of a chlorhexidine-impregnated dressing compared with conventional dressings for prevention of catheter colonization and catheter-related bloodstream infection. Data Extraction: Data were extracted on patient and catheter characteristics and outcomes. Data Synthesis: Nine randomized controlled trials met the inclusion criteria. Use of a chlorhexidine-impregnated dressing resulted in a reduced prevalence of catheter-related bloodstream infection (random effects relative risk, 0.60; 95% CI, 0.41-0.88, p = 0.009). The prevalence of catheter colonization was also markedly reduced in the chlorhexidine-impregnated dressing group (random effects relative risk, 0.52; 95% CI, 0.43-0.64; p < 0.001). There was significant benefit for prevention of catheter colonization and catheter-related bloodstream infection, including arterial catheters used for hemodynamic monitoring. Other than in low birth weight infants, adverse effects were rare and minor. Conclusions: Our analysis shows that a chlorhexidine-impregnated dressing is beneficial in preventing catheter colonization and, more importantly, catheter-related bloodstream infection and warrants routine use in patients at high risk of catheter-related bloodstream infection and central venous catheter or arterial catheter colonization. (Crit Care Med 2014; 42:1703-1713) Key Words: catheter-related infection; chlorhexidine; nosocomial infection I ntravascular catheters are often needed in patients of all ages requiring intensive care, parenteral alimentation, cancer chemotherapy, organ transplantation, home antibiotic therapy, or hemodialysis (1-3). An estimated 5 million U.S. patients require either short-term or prolonged central venous access each year (4) (5) (6) (7) .
Although vital to care, these devices are associated with risk of catheter-related bloodstream infection (CRBSI) (3, 6, 7) . CRBSIs directly increase antibiotic exposure, length of stay, and healthcare costs and may increase mortality (8) (9) (10) (11) . CRBSI is increasingly recognized as a preventable healthcare-associated infection (12) , prompting the United States Centers for Medicare and Medicaid Service to cease reimbursing healthcare institutions for these complications as of October 2008. There is an urgent need for effective strategies to prevent CRBSI (13, 14) .
The most common route of infection occurs at insertion when skin organisms invade the percutaneous tract extraluminally via capillary action. During regular use, contamination of the hub and lumen can occur whenever the catheter is manipulated, such as when an infusion is started, or when the central venous catheter (CVC) is manipulated with a guidewire. Finally, organisms can be carried hematogenously to the implanted device from remote sources of infection, for example, pneumonia or urinary tract infection (15) (16) (17) (18) (19) .
Understanding these mechanisms of CRBSI, pathogenesis has led to specific preventive strategies, including the creation of best practice guidelines and evidence-based "bundles" such as those developed by the Institute for Healthcare Improvement (4, 20, 21) . These include an emphasis on hand hygiene, the use of full-barrier precautions during catheter insertion, skin antisepsis using chlorhexidine, preferential use of the subclavian/ internal jugular sites for nontunneled catheters, and daily evaluation of catheter necessity with prompt removal of unnecessary catheters (4, 20) .
Strict adherence to evidence-based best practices clearly reduces CRBSI rates (3, 12, (22) (23) (24) (25) (26) . Individual interventions that can make CRBSI prevention simpler and more cost effective merit further investigation. A promising intervention directed at reducing the extraluminal route of infection is a chlorhexidine gluconate-impregnated dressing placed at the time of CVC insertion (27) (28) (29) , which releases chlorhexidine onto the skin for a 10-day period (30) . Studies on the efficacy of a chlorhexidine-impregnated dressing for reducing CRBSI have had conflicting results (31) (32) (33) (34) (35) (36) (37) (38) . We undertook a meta-analysis to examine the efficacy of a chlorhexidine-impregnated dressing compared with conventional site care for prevention of CRBSI and catheter colonization.
METHODS

Search Strategy
This study was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (39) . The search strategy was developed with the assistance of an expert librarian (for search details, see online supplementary material, Supplemental Digital Content 1, http://links. lww.com/CCM/A880).
Inclusion Criteria
Included studies were prospective randomized trials comparing a chlorhexidine-impregnated dressing with conventional site care. Included studies had to provide microbiologically based definitions for CRBSI and systematically report the prevalence of CRBSI in both comparator and control arms. Authors of potentially relevant studies were contacted for further information if some of these data were unpublished. Case-control, case reports, reviews, retrospective studies, and nonrandomized prospective trials were excluded.
Outcome Measures
The primary outcome measure was CRBSI. Catheter colonization was identified as a secondary outcome. The definitions of CRBSI and catheter colonization were as provided by the individual studies.
Data Extraction
Three investigators (N.S., A.G., J.O.) independently abstracted data on the size of the study sample, patient population, type of vascular devices, dressing, cutaneous antiseptic used, device use duration, prevalence of catheter colonization, and prevalence of CRBSI. The authors of studies that did not report prevalence data for analysis were contacted for additional information.
We evaluated the included studies for methodological quality using the recommendations outlined in the Cochrane Handbook of Systematic Review (40) . The risk of bias in each study was assigned as either low or high. Three authors (N.S., A.G., J.O.) independently reviewed each report identified by the above-mentioned search strategy. Disagreements among abstracters regarding values or analysis assignments were resolved by discussion.
Statistical Analysis
Pooled estimates of the relative risk (RR) and 95% CI were obtained using the DerSimonian and Laird random effects model (41) . Some studies included patients who had more than one vascular catheter during the study period. For these studies, we inflated the variance of the risk ratio to adjust for within-patient correlation (42, 43) . Heterogeneity was assessed using the Cochran Q statistic and I 2 (40) . 
RESULTS
Study Selection
The database search retrieved 505 unique citations of which seven met our inclusion criteria, described in Figure 1 (31, (33) (34) (35) (36) (37) (38) . Manual search of references of included studies identified two additional studies (32, 46) . Excluded studies fell into one or more of the following exclusionary categories: nonrandomized trial (n = 8), chlorhexidine solution or impregnated catheters rather than dressing (n = 108), chlorhexidine for indications other than intravascular devices (n = 126), review article (n = 42), editorial or letter (n = 13), study population or outcome not meeting selection criteria (n = 7), or unrelated to intravascular device use (n = 194).
Study Characteristics
The nine trials enrolled 6,067 patients with a total of 11,214 catheterizations; 5,586 catheters in 2,984 patients received a chlorhexidine-impregnated dressing and 5,628 catheters in 3,083 patients received conventional site care. Two large studies accounted for more than half the patient population (35, 46) . Two studies were conducted in neonates, infants, or children (31, 33) , two in adult patients with malignancy (34, 37) , and five in adult medical-surgical and cardiothoracic ICUs (32, 35, 36, 38, 46) .
The characteristics of the nine randomized controlled trials are summarized in Table 1 . Five studies (32, 34, 36, 38, 46) recorded catheter colonization and CRBSI using the catheter as the unit of analysis, while three of the included trials (31, 33, 37) reported the data using the patient as the unit of analysis. One study reported the outcome measures for both patients and catheters (35) .
The mean duration of catheterization varied between the studies but was similar within the control and intervention groups of each individual trial. These are reported in Table 2 .
All studies used standard aseptic technique in inserting catheters, including cutaneous antisepsis. The different topical antisepsis agents are summarized in Table 1 . One study used different skin preparations for the comparator (povidone-iodine) and treatment (70% isopropyl alcohol) arms (31) .
The subclavian or internal jugular sites were the preferred central venous access site in most studies (32, 33, 35, 37, 46) . Only one study used the femoral site predominantly (36) , and one used primarily peripherally inserted central catheters (PICCs) (31) . Two studies did not specify the sites used (34, 38) . The trial by Maki et al (32) included central venous, PICCs, pulmonary artery, and peripheral arterial catheterizations.
With the exception of one study that used no dressing (34) , all the other trials used occlusive dressings as the comparator. Dressing changes were conducted at 7-day intervals in three studies (31, 33, 37), 3-day intervals for one study (36) , and 5-day intervals for one study (38) . One study varied the interval by assignment, with 7-day changes in the experimental group and 2-day intervals in the control group (32) . Two studies were randomized control trials with both 3-and 7-day dressing change intervals (35, 46) .
The majority of patients analyzed in this meta-analysis were patients in ICUs, both pediatric and adult patients in seven of the nine included trials (31-33, 35, 36, 38, 46) . Duration of catheterization ranged from 5.6 (33) to 71.5 days (34).
Details of Randomization
Block randomization was used in seven trials (31-33, 35-37, 46 ). In the remaining two studies, the method of randomization was not given (34, 38) . Single blind methodology was employed in review of cultures and/or data in four studies (33, 35, 36, 46) . Intention-to-treat analysis was described in five trials (31, 32, 34, 35, 46) .
Study Quality
Two of the included studies were determined to have a high risk of bias due to high baseline infections and nonstandard infection control practices (34, 37) , whereas the remaining seven studies were classified as low risk. The risk assessments of the individual studies are listed in Table 1 .
Three large studies (32, 35, 47) accounted for 83% of the included patients. All three of these studies were designated as having a low risk of bias.
Diagnosis of Catheter Colonization and CRBSI
The authors used various definitions for catheter colonization and CRBSI in the included studies (Table 1) . One study provided no definition for catheter colonization, other studies defined it as catheter tip culture yielding greater than 15 colonies or greater than or equal to 1,000 colony-forming units per milliliter (CFU/mL). Another two used a lower cutoff of 100 CFU/mL using the Sherertz technique (35, 46) . Roberts and Cheung (38) defined catheter colonization nonquantitatively as isolation of the same organism from exit site and catheter tip without obvious signs of infection.
CRBSI was defined by Chambers et al (34) as positive blood cultures drawn in the presence of fever with no other recognized focus of infection, causing premature removal of the catheter and the catheter tip, yielding greater than 15 CFU/ mL of the same organism. Similar definitions were used in the studies by Arvaniti et al (36), Garland et al (31), Levy et al (33) , and Maki et al (32) . Roberts and Cheung (38) identified CRBSI as any infection yielding the same organism from the CVC tip/ exit site and a blood culture isolate and associated with fever and elevated WBC count. Ruschulte et al (37) used blood cultures drawn both percutaneously and from the catheter, with a differential time to positivity of greater than 2 hours. Timsit et al (35, 47) used the following definition: positive blood cultures sampled 48 hours before or 48 hours after catheter removal with a quantitative catheter tip culture yielding the same microorganisms or a differential time to positivity of blood cultures greater than or equal to 2 hours, without any other focus of infection. Figure 2 .
001). This is illustrated as a forest plot in
Prevalence of CRBSI
Overall, 1.1% of patients (64 of 5,639) developed CRBSI in the treatment group compared with 2.1% of patients (120 of 5,608) in the comparator group. Six of the nine trials had results favoring the chlorhexidine-impregnated dressing for reducing CRBSI. The RR for CRBSI comparing the chlorhexidine and comparator groups in the meta-analysis was 0.60 (95% CI, 0.41-0.88; p = 0.009), depicted as a forest plot in Figure 3 .
Publication Bias
Funnel plots (Fig. 4) did not indicate publication bias to be likely. Eggers test was not statistically significant (p = 0.15).
Assessment of Heterogeneity
There was substantial clinical heterogeneity in the included studies with differing patient populations, protocols for catheter care, and definitions of colonization. I 2 for colonization was moderate at 54%. For CRBSI, heterogeneity was low (I 2 = 17%). Only two studies failed to demonstrate a reduction in colonization with impregnated sponges. The first had a small sample size, and authors stated that the study was not adequately powered to make a definitive statement about chlorhexidine dressing efficacy (38) . The second study attributed the lack of effect to avoidance of femoral catheterization sites, smaller percentage of trauma patients, and use of povidone-iodine skin antisepsis prior to cannulation (36) .
Subgroup Analysis
To explore the reasons for heterogeneity, we undertook three subgroup analyses limited to studies assessing the efficacy of the chlorhexidine-impregnated dressing for 1) prevention of CRBSI in patients with malignancy, 2) in adult ICU patients only, and 3) in PICU patients only.
Using a random effects model to analyze data from the two studies in patients with hematologic malignancy (34, 37), we found a statistically significant benefit with the use of chlorhexidine-impregnated dressing. The RR was 0.53 (95% CI, 0.32-0.89; p = 0.02).
Five studies were limited to adult ICU populations (32, 35, 36, 38, 46) and the chlorhexidine-impregnated dressing was associated with an RR of 0.45 (95% CI, 0.28-0.72). In the pediatric population, the chlorhexidine-impregnated dressing was not associated with a statistically significant reduction in bloodstream infection (BSI) (RR, 1.21; 95% CI, 0.60-2.44) (31, 33) . Duration of catheterization was reported in all but two studies. Catheterization averaged longer than 2 weeks in three studies (31, 34, 37) . In that subgroup, there was not an appreciable impact on rates of BSI (RR = 0.68; 95% CI, 0.36-1.30). In the remaining five studies (33, 35, 36, 38, 46) , the benefit of chlorhexidine dressings was more pronounced (RR = 0.52; 95% CI, 0.30-0.90).
Microbiology and Resistance to Chlorhexidine
Staphylococcus epidermidis was the most common organism isolated, followed by Staphylococcus aureus, other Gram-positive cocci, and Escherichia coli. None of the studies reported prevalence of resistance to chlorhexidine. However, routine surveillance by Chambers et al (34) before and after catheterization grew one isolate of micrococcus at 1 month in 0.01% chlorhexidine broth but did not grow at subsequent concentrations.
Adverse Effects of Chlorhexidine
Contact dermatitis from the chlorhexidine-impregnated dressing was the most common adverse effect reported in studies (31, 35, 46) . Timsit et al (35) found the prevalence of severe contact dermatitis requiring catheter removal to be 5.3 per 1,000 catheters. The second study by Timsit et al (47) found a similar low event rate of contact dermatitis (5.0 of 1,000 catheters) and no systemic reactions. Garland et al (31) reported a much higher prevalence of 19 of 335 neonates (5.7%). Birth weight of all seven neonates who developed contact dermatitis in the initial 15 months of the study was 880 g or less with a gestational age less than 27 weeks with CVCs placed on day 8 of life or earlier. The observation of an adverse reaction in premature babies with extremely low birth weights led to a change in the inclusion criteria for the study, and thereafter, infants less than 26 weeks of gestation were enrolled in the study only if CVC was inserted after the first week of life. Overall, in the treatment group, 15 of 98 neonates (15%) with birth weight less than 1,000 g developed contact dermatitis versus four of 237 neonates (1.5%) greater than or equal to 1,000 g (p < 0.0001). Garland et al (31) also reported pressure necrosis in two cases. No systemic reactions to chlorhexidine were observed.
DISCUSSION
In this meta-analysis, a chlorhexidine-impregnated dressing was significantly more effective than traditional site care for preventing vascular catheter colonization and CRBSI. The relative risk reduction was 45% for CRBSI and 48% for catheter colonization. The pooled absolute risk reduction in CRBSI was 1.3%, making the number needed to treat 77.
Our findings suggest that a chlorhexidine-impregnated dressing can provide considerable value in reducing the risk of CRBSI in patients with central vascular catheters. A chlorhexidine-impregnated dressing is expected to be of greatest benefit in a setting where the extraluminal route of infection is expected to predominate such as short-term catheters. Garland et al, in a subcohort analysis, found that the differences in catheter tip colonization, an accepted surrogate for CRBSI, between the treatment and control groups were most evident for neonates whose catheters were in situ less than or equal to 14 days (11% vs 25%; p = 0.0007); there were no differences between the treatment and control groups when the catheter was in situ longer than 14 days (23% vs 20%; p = 0.53) (3). This analysis suggests that there may be little or no advantage to using a chlorhexidine-impregnated dressing on a catheter in place beyond 14 days. This likely corresponds to a change in the pathogenesis of CRBSI from the extraluminal route (27) associated with short-term CVCs to the intraluminal route (17) . The benefits of chlorhexidine-impregnated dressings would not be expected to have as much impact on CRBSI rates when the intraluminal route is the primary source of infection, as is the case with long-term devices and any CVC after the first or second week of insertion with routine dressing changes.
Most studies in our analysis used a chlorhexidine-impregnated sponge dressing (Biopatch, Johnson and Johnson, New Brunswick, NJ), and one study used an integrated chlorhexidine dressing (3M Tegaderm Chlorhexidine Dressing, 3M, St Paul, MN) (46) . We included both types in our analyses as the mechanism of activity would be expected to be similar. The Biopatch dressing comes as a round sponge that is placed circumferentially around the insertion site. Errors in placement and dressing disruption have been well described with a sponge dressing (48) . At our institution, we have been using the sponge dressing for over a decade and continue to witness wrong placement of the dressing. An integrated chlorhexidine dressing obviates this problem but may have its own limitations such as difficulty in removal.
To our knowledge, ours is the first meta-analysis to examine the impact of a chlorhexidine dressing including both a sponge dressing and an integrated dressing. Ho et al (49) previously demonstrated a nonstatistically significant trend toward reduction in CRBSI with the use of chlorhexidineimpregnated sponge dressings. This analysis includes seven studies evaluated by this previous analysis and includes two additional, recently published large studies. This study excluded one included in Ho et al (49) , which evaluated skin colonization as its endpoint, because it did not evaluate catheter colonization or CRBSI, the main outcomes for this analysis.
Chlorhexidine-impregnated dressings must be viewed as an adjunct to the sum total of essential preventive measures shown to reduce CRBSI and do not replace insertion and maintenance best practices. But even if a high rate of compliance with best practices has been achieved, two of the most recent trials found a substantial and highly statistically significant reduction in CRBSI, with a very low baseline rate of CRBSI.
It is important to ascertain whether the benefit of the chlorhexidine-impregnated dressing is confined to a particular type of vascular catheter. In the three studies that included arterial catheters (32, 35, 46) , the beneficial effect As reported in the study after adjusting for correlation.
of the chlorhexidine-impregnated dressing extended also to peripheral arterial catheters, suggesting that use of the chlorhexidine-impregnated dressing on arterial catheters warrants consideration. Consideration of adverse effects of topical prolonged exposure to chlorhexidine is essential and adverse effects were explicitly addressed in three published clinical trials included in our meta-analysis (31, 35, 46) . Reported adverse effects of cutaneous use of chlorhexidine include contact dermatitis and pressure necrosis. These adverse reactions were encountered in approximately 15% of cases in a randomized trial of a chlorhexidine-impregnated sponge dressing in premature neonates with birth weight less than 1,000 g and suggest that a chlorhexidine-impregnated dressing should be used with caution in this population. Generally, chlorhexidine-impregnated dressings for prevention of CRBSI appear to be safe and well tolerated; however, clinicians should remain vigilant for erythema and dermatitis at the site of the chlorhexidine-impregnated dressing.
Another potential concern associated with the prolonged use of antiseptic agents is the emergence of microbial resistance (50) . Frequent exposure to chlorhexidine may result in development of resistance to biocides (51, 52) . However, in clinical trials of chlorhexidine-impregnated vascular devices, resistance to chlorhexidine has not been detected (53, 54) . A recent well-designed trial comparing a second-generation CVC impregnated with chlorhexidine and silver sulfadiazine with a standard uncoated catheter for prevention of CRBSI included rigorous efforts to detect antiseptic resistance (53) . The investigators found that the zones of inhibition to chlorhexidine were similar for organisms recovered from both the antiseptic and control catheters. However, in vitro studies of Pseudomonas stutzeri exposed to slowly increasing concentrations of chlorhexidine found emergence of resistance to chlorhexidine and several classes of therapeutic antimicrobial agents (55) . None of the published clinical trials included in our analysis adequately assessed emergence of resistance to chlorhexidine among isolates recovered from blood or catheter segments. Although low-level bacterial chlorhexidine resistance (56) and resistance genes encoding chlorhexidine resistance (57) have been identified, there have been no reports of clinically relevant chlorhexidine resistance to date (57, 58) , despite the widespread use of chlorhexidine for cutaneous disinfection vascular access sites and surgical sites, and in recent years, total body bathing of patients in critical care units (59) (60) (61) . The increasing use of chlorhexidine makes continued surveillance for developing resistance important (57), but, as the microbial populations beneath a chlorhexidine dressing are minute following cutaneous disinfection, it seems unlikely that the use of chlorhexidine sponge dressings for prevention of vascular catheter-related BSI will contribute materially to the emergence and spread of chlorhexidine-resistant nosocomial pathogens.
There are several limitations to our analyses that warrant consideration. Although one of the studies blinded the investigators evaluating the data (32) , and two blinded assessors (35, 46) , none of the included studies were truly double blind, increasing risk of bias. Two studies reported that blinded laboratory personnel performed cultures, and one study used a blinded case report review; however, the influence of the presence of the dressing on the clinician's suspicion and decision to investigate CRBSI is unknown (33, 35) . Only two studies performed a comprehensive epidemiologic evaluation of the CRBSI source by sampling the catheter hub and performing molecular identification of isolated coagulase-negative staphylococci to establish concordance between strains found in the blood, catheter tip, and hub (31, 32) . Additional limitations include the varied populations, settings, catheter types, and reasons for use. Another significant limitation is the variable rates of catheter-related infections seen across studies, with control-group CRBSI rates ranging from 0% to 13%. Differences in local practice and prevention guideline implementation over time may account for this difference.
These limitations notwithstanding, our results have important implications for clinicians involved in the care of patients with intravascular catheters and highly support the use of a chlorhexidine-impregnated dressing. Our analyses support the routine use of a chlorhexidine-impregnated dressing for the prevention of CRBSI as part of a comprehensive approach to reducing CRBSI. Future research needs to undertake comparative effectiveness and cost-effectiveness studies to determine which of the available multiple novel technologies and prevention strategies, alone or in combination, provide the most impact for reducing CRBSI and better identify subgroups of patients most likely to benefit.
